Bone marrow-derived mononuclear cells for ischemic cardiomyopathy

The study hypothesis is that transendocardial injections of autologous mononuclear bone marrow cells in patients with end-stage ischemic heart disease is safe, can promote neovascularization, and can improve perfusion and myocardial contractility. The primary object of this study was to evaluate the safety of autologous bone marrow mononuclear cell injections and the ability to improve cardiac contractile function and functional outcomes. In treated patients, the left ventricular ejection fraction increased. The therapy was found to be safe and reduced symptoms, and improved quality of life, and possibly improved perfusion in patients.